On September 27, 2022, Isoray, Inc. (the “Company” or “ Isoray”) entered into an Agreement and Plan of Merger (the “ Merger Agreement”) by and among the Company, Isoray Acquisition Corp., and wholly-owned subsidiary of the Company (“ Merger Sub”), Viewpoint Molecular Targeting, Inc. Upon the Closing, Isoray will increase the size of its Board of Directors from 4 members to not less than 5 members. 3 of the directors will be designated by Isoray and 2 of the directors will be designated by Viewpoint. Also upon the Closing, Lori Woods will resign from her position as CEO of Isoray and Thijs Spoor will be named CEO of Isoray.